UCSF scientists wiped out an aggressive childhood brain cancer in mice using a new immune cell therapy.
The treated mice also rejected new cancer cells weeks later.
Human clinical trials could begin as early as April 2027.
Scientists at UC San Francisco have eliminated diffuse midline glioma, one of the most lethal childhood brain cancers, in mice with an engineered immune cell therapy that switches on only inside the brain.
Pediatric Neuro-Oncologist on the Results: "This preclinical data is very promising. Mice with DMG are being cured, and we are incredibly excited to bring this therapy to the children and young adults we care for." — Dr. Sabine Mueller, Director, UCSF Pediatric Brain Tumor Center.
Neurosurgeon on the Design: "By limiting B-SYNC's CAR expression to when and where it matters—in the brain—we saw consistent, total shutdown of DMG tumors in the lab." — Hideho Okada, professor of Neurological Surgery, UCSF.
Focus Area: The B-SYNC CAR-T therapy and its path from mouse experiments to human trials.
The therapy, called B-SYNC CAR-T, uses a sensor that triggers production of cancer-targeting receptors only when it detects brevican, a protein found throughout the brain.
Once activated, the cells hunt tumor cells carrying the proteins EphA2 and IL13Rα2. In cells circulating in the blood or present in the spleen, the receptors were not produced, as designed. The study was published in Science Translational Medicine.
When given directly into the brain, the treatment completely eliminated tumors in every mouse across two models containing human DMG cells, while conventional CAR-T cells failed to control them.
Nearly seven weeks later, researchers introduced new cancer cells, and every treated mouse rejected them. B-SYNC cells remained functional more than 70 days after treatment.
The team is now preparing human trials with UCSF cancer specialists, using each patient's own T cells modified into B-SYNC CAR-T cells.
The first trial, co-led by Mueller, could start as early as April 2027 and will compare intravenous delivery with direct administration into the brain.
The therapy has not yet been tested for effectiveness in humans.
Diffuse midline glioma grows in the brainstem, which controls breathing, heartbeat, and swallowing.
Nearly all children diagnosed die within a year, and existing treatments have had little success. B-SYNC was first developed for glioblastoma, another brain cancer that shares the same tumor markers.
Follow Channel8 for continuous updates:
Scientists Map 539 Distinct Chemical Zones in Mouse Brain
Scientists Find Potential Weak Point in Alzheimer’s-Linked Protein
Blood-Based Sensor Detects Parkinson’s-Linked Proteins in 40 Minutes

